Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SAN DIEGO, Feb. 23, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016 at 11:20 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's marketed products, Chenodal®, Cholbam® and Thiola®.
Retrophin.com
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
